194 related articles for article (PubMed ID: 21190039)
1. Educational paper. The development of new therapies for pediatric oncology.
Horton TM; Berg SL
Eur J Pediatr; 2011 May; 170(5):555-9. PubMed ID: 21190039
[TBL] [Abstract][Full Text] [Related]
2. Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma.
Moreno L; Barone G; DuBois SG; Molenaar J; Fischer M; Schulte J; Eggert A; Schleiermacher G; Speleman F; Chesler L; Geoerger B; Hogarty MD; Irwin MS; Bird N; Blanchard GB; Buckland S; Caron H; Davis S; De Wilde B; Deubzer HE; Dolman E; Eilers M; George RE; George S; Jaroslav Š; Maris JM; Marshall L; Merchant M; Mortimer P; Owens C; Philpott A; Poon E; Shay JW; Tonelli R; Valteau-Couanet D; Vassal G; Park JR; Pearson ADJ
Eur J Cancer; 2020 Sep; 136():52-68. PubMed ID: 32653773
[TBL] [Abstract][Full Text] [Related]
3. New targets and targeted drugs for the treatment of cancer: an outlook to pediatric oncology.
Rossig C; Juergens H; Berdel WE
Pediatr Hematol Oncol; 2011 Oct; 28(7):539-55. PubMed ID: 21936619
[TBL] [Abstract][Full Text] [Related]
4. Target and Agent Prioritization for the Children's Oncology Group-National Cancer Institute Pediatric MATCH Trial.
Allen CE; Laetsch TW; Mody R; Irwin MS; Lim MS; Adamson PC; Seibel NL; Parsons DW; Cho YJ; Janeway K;
J Natl Cancer Inst; 2017 May; 109(5):. PubMed ID: 28376230
[TBL] [Abstract][Full Text] [Related]
5. [Kinase inhibitors in oncology : What is new?].
Riedmann K; Bassermann F; Jost PJ
Internist (Berl); 2019 May; 60(5):540-544. PubMed ID: 30859279
[TBL] [Abstract][Full Text] [Related]
6. Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia.
Maddocks K; Jones JA
Semin Oncol; 2016 Apr; 43(2):251-9. PubMed ID: 27040703
[TBL] [Abstract][Full Text] [Related]
7. Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.
Parsons K; Bernhardt B; Strickland B
Ann Pharmacother; 2013 Feb; 47(2):210-8. PubMed ID: 23386066
[TBL] [Abstract][Full Text] [Related]
8. Management of relapsed acute lymphoblastic leukemia in childhood with conventional and innovative approaches.
Locatelli F; Moretta F; Rutella S
Curr Opin Oncol; 2013 Nov; 25(6):707-15. PubMed ID: 24076579
[TBL] [Abstract][Full Text] [Related]
9. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
10. Opportunities and Challenges in Drug Development for Pediatric Cancers.
Laetsch TW; DuBois SG; Bender JG; Macy ME; Moreno L
Cancer Discov; 2021 Mar; 11(3):545-559. PubMed ID: 33277309
[TBL] [Abstract][Full Text] [Related]
11. Physiologically Based Pharmacokinetic Modeling in Pediatric Oncology Drug Development.
Rioux N; Waters NJ
Drug Metab Dispos; 2016 Jul; 44(7):934-43. PubMed ID: 26936973
[TBL] [Abstract][Full Text] [Related]
12. Bruton's tyrosine kinase inhibitors in B-cell non-Hodgkin's lymphomas.
Alinari L; Quinion C; Blum KA
Clin Pharmacol Ther; 2015 May; 97(5):469-77. PubMed ID: 25670208
[TBL] [Abstract][Full Text] [Related]
13. The Challenge of Developing New Therapies for Childhood Cancers.
Balis FM
Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
[TBL] [Abstract][Full Text] [Related]
14. Japan society of clinical oncology/Japanese society of medical oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors, cooperated by the Japanese society of pediatric hematology/oncology.
Naito Y; Mishima S; Akagi K; Igarashi A; Ikeda M; Okano S; Kato S; Takano T; Tsuchihara K; Terashima K; Nishihara H; Nishiyama H; Hiyama E; Hirasawa A; Hosoi H; Maeda O; Yatabe Y; Okamoto W; Ono S; Kajiyama H; Nagashima F; Hatanaka Y; Miyachi M; Kodera Y; Yoshino T; Taniguchi H
Int J Clin Oncol; 2020 Mar; 25(3):403-417. PubMed ID: 31974683
[TBL] [Abstract][Full Text] [Related]
15. Old Tyrosine Kinase Inhibitors and Newcomers in Gastrointestinal Cancer Treatment.
Giordani E; Zoratto F; Strudel M; Papa A; Rossi L; Minozzi M; Caruso D; Zaccarelli E; Verrico M; Tomao S
Curr Cancer Drug Targets; 2016; 16(2):175-85. PubMed ID: 26278713
[TBL] [Abstract][Full Text] [Related]
16. Targeting receptor tyrosine kinases in solid tumors.
Zhang J; Hochwald SN
Surg Oncol Clin N Am; 2013 Oct; 22(4):685-703. PubMed ID: 24012395
[TBL] [Abstract][Full Text] [Related]
17. New approaches to drug development in pediatric oncology.
Adamson PC; Blaney SM
Cancer J; 2005; 11(4):324-30. PubMed ID: 16197722
[TBL] [Abstract][Full Text] [Related]
18. Clofarabine and nelarabine: two new purine nucleoside analogs.
Gandhi V; Plunkett W
Curr Opin Oncol; 2006 Nov; 18(6):584-90. PubMed ID: 16988579
[TBL] [Abstract][Full Text] [Related]
19. Novel approaches to the development of tyrosine kinase inhibitors and their role in the fight against cancer.
Zámečníkova A
Expert Opin Drug Discov; 2014 Jan; 9(1):77-92. PubMed ID: 24294890
[TBL] [Abstract][Full Text] [Related]
20. Evolving paradigms for new agent development in pediatric oncology.
Flynn A; Fox E
Curr Opin Pediatr; 2018 Feb; 30(1):10-16. PubMed ID: 29176356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
